Skip to Navigation Skip to Search Skip to Content
Search All Centers

Ask the Expert: What Happens If I Become Resistant to Ibrutinib?

Published on October 16, 2017

Which additional CLL treatment options are available for patients who develop resistance to ibrutinib (Imbruvica)? In this “Ask the Expert” session, Dr. Michael Keating, a leading CLL expert from The University of Texas MD Anderson Cancer Center, explains alternative inhibitor approaches if a patient becomes resistant. Dr. Keating also explains the role of monoclonal antibodies.

This Ask the Expert series is a Patient Empowerment Network program produced by Patient Power.   We thank AbbVie and Genentech for their support.

Featuring

Thank you, Andrew and team, for creating the best information source on the web for CLL!

— John, CLL town meeting attendee

Sponsors

Patient Empowerment Network

You might also like